🧪 Elizabeth Holmes and Balwani ordered to pay $452M for Theranos

Elizabeth Holmes and her former deputy Ramesh "Sunny" Balwani were ordered by a federal judge to pay $452 million in restitution to the investors defrauded by Theranos, the blood-testing company Holmes founded in 2003 and ran into the ground by 2018.

The verdict

A jury in the U.S. District Court for the Northern District of California convicted Holmes on January 3, 2022, of three counts of wire fraud and one count of conspiracy to commit wire fraud, all tied to defrauding investors. She was acquitted on four counts related to defrauding patients, and the jury could not reach a verdict on three further counts, on which the judge declared a mistrial.

The sentence

In November 2022, U.S. District Judge Edward Davila sentenced Holmes to 11 years and 3 months in federal prison, to be served at the minimum-security Federal Prison Camp in Bryan, Texas. Holmes appealed to the U.S. Court of Appeals for the Ninth Circuit, which rejected her arguments and affirmed both the conviction and the sentence in February 2025. In March 2026, Davila cut the sentence by 12 months, citing revised federal sentencing guidelines and the prosecution's failure to show that any investor suffered personal hardship from the loss of their money. Balwani, tried separately, was convicted on all 12 counts against him in July 2022 and sentenced that December to 12 years and 11 months in prison.

The restitution order

Alongside Holmes's criminal sentence, Davila ordered her and Balwani to jointly pay $452 million in restitution to the fraud's victims. That figure sits apart from the civil case the SEC brought against Holmes in March 2018, which she settled by paying a $500,000 fine, returning 18.9 million Theranos shares and accepting a ten-year ban on serving as an officer or director of a public company - without Holmes admitting or denying the SEC's findings.

"deceived investors into believing that its key product – a portable blood analyzer – could conduct comprehensive blood tests from finger drops of blood"

SEC press release, March 2018

What investors actually lost

Theranos raised more than $700 million from investors, according to the SEC, and was valued at $9 billion at its peak. Newly unsealed documents in a 2016 investor class-action suit, reported by The New York Times in May 2018, showed high-profile backers had collectively lost hundreds of millions of dollars.

Smaller settlements piled up before the company folded: Theranos agreed in 2017 to return $4.65 million to Arizona consumers - all amounts they had paid for its tests - plus $200,000 in civil penalties and $25,000 in fees, settling without admitting liability, and it settled a Walgreens breach-of-contract suit - which had sought $140 million - for less than $30 million. The company that promised to replace the needle ended up writing a great many checks instead.

Theranos announced its dissolution in September 2018, telling shareholders in an email that it would pay out its remaining cash to unsecured creditors in the months that followed.